‘Surprisingly high’ remission rates for both ustekinumab, adalimumab in Crohn’s patients

Ustekinumab and adalimumab demonstrated equally high rates of clinical remission in biologic-naïve patients with moderate to severe Crohn’s disease through 1 year of treatment, according to results of the SEAVUE study in The Lancet.“Although SEAVUE did not demonstrate superior efficacy of ustekinumab over adalimumab, both agents showed surprisingly high rates of clinical remission at 1…

FDA grants orphan drug designation to rencofilstat for hepatocellular carcinoma

The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.Rencofilstat (Hepion Pharmaceuticals), a novel, potent cyclophilin inhibitor, is in clinical-phase development for treatment of nonalcoholic steatohepatitis (NASH), a major cause of HCC.The agent has been shown in experimental NASH models to lower liver fibrosis and HCC tumor…

VIDEO: LGBTQ+ mentorship key to help medical trainees be comfortably ‘out,’ GI fellow says

In this video, Nikki Duong, MD, a gastroenterology fellow at Virginia Commonwealth University, shares his experience being “out” in the medical field and what he feels is necessary to create a more inclusive environment for LGBTQ+ trainees.Duong noted that within medicine there is a lack of LGBTQ+ trainees — and even fewer go into gastroenterology…